BiotechTube
Convergent Genomics

Convergent Genomics

San Diego, United States· Est.
convergentgenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $123M

Overview

Convergent Genomics is a private, commercial-stage diagnostic company developing non-invasive liquid biopsy tests for cancer detection and monitoring. Its lead product, UroAmp, is a genomic urine test for detecting Minimal Residual Disease (MRD) and recurrence in bladder cancer patients, leveraging next-generation sequencing and machine learning. The company is led by a team of cancer biologists, urologic oncologists, and data scientists, and its technology aims to shift cancer care from reactive treatment to proactive prediction and early intervention. Convergent Genomics appears to be in an early revenue phase, commercializing its UroAmp test while building clinical evidence.

Urologic OncologyBladder Cancer

Technology Platform

Liquid biopsy platform utilizing next-generation sequencing (NGS) and machine learning algorithms to analyze cell-free DNA from urine for the detection, monitoring, and risk prediction of urothelial cancer.

Funding History

3
Total raised:$123M
PIPE$90M
Series A$25M
Seed$8M

Opportunities

The large, costly bladder cancer patient population creates a significant market for a non-invasive monitoring test that can reduce invasive cystoscopies and enable earlier intervention.
The company's focused urine-based platform is a differentiated entry point into the liquid biopsy market and could be expanded to other urologic cancers.
Demonstrating improved outcomes and cost savings could lead to rapid adoption and new standards of care.

Risk Factors

Key risks include securing consistent insurance reimbursement, which is critical for commercial viability, and overcoming clinician reliance on traditional surveillance methods like cystoscopy.
The company also faces competition from larger liquid biopsy firms and the risk that future studies may not validate the test's performance in broader populations.

Competitive Landscape

Convergent operates in the competitive liquid biopsy and cancer diagnostics space, competing with large public companies like Guardant Health and Exact Sciences that offer blood-based tests. Its primary differentiation is the urine-based, bladder-cancer-specific focus for MRD monitoring, a niche less served by broad pan-cancer blood tests. It must also compete against standard-of-care methods like cystoscopy and cytology.

More companies in Diagnostics & Precision Medicine →More companies in United States →